Table 3.
Association of rs1646724 with ACM in patients with advanced prostate cancer treated with ADT
| SNP Genotype | n | ACM | 5‐year survival rate, % | HR (95% CI)a | P a |
|---|---|---|---|---|---|
| rs1646724 | |||||
| TT | 265 | 69 | 73.0 | 1.00 | |
| TG | 195 | 64 | 70.5 | 1.27 (0.89‐1.81) | .193 |
| GG | 40 | 14 | 61.6 | 2.03 (1.07‐3.83) | .030 |
| TG/GG vs TT | 1.35 (0.95‐1.90) | .091 | |||
| GG vs TT/TG | 1.80 (0.98‐3.30) | .058 | |||
| Trend | 1.35 (1.03‐1.78) | .032 | |||
ACM, all‐cause mortality; ADT, androgen deprivation therapy; HR, hazard ratio; CI, confidence interval; PSA, prostate‐specific antigen.
a
Adjusted by age, PSA at ADT initiation, Gleason score, stage, PSA nadir and treatment modality.
P < .05 are in boldface.